Reversing Glucose and Lipid-mediated Vascular Dysfunction
Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Apr 2, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how glucose and fat in our diet affect blood vessels in healthy adults and if these changes can lead to high blood pressure. Researchers want to understand the connection between these factors to help prevent hypertension in the future. The trial is currently looking for participants who are lean, with a Body Mass Index (BMI) under 25, and who have normal blood pressure and insulin sensitivity. Eligible participants should be between 18 and 79 years old and have stable weight over the last three months.
If you decide to join the study, you may need to stop taking certain supplements for two weeks before participating. As a participant, you can expect to undergo assessments to measure how your blood vessels respond to glucose and fat. It's important to note that individuals with diabetes, high blood pressure, a history of heart or vascular disease, or current smokers cannot participate. This study aims to provide valuable insights into how diet affects blood vessel health, which could lead to better ways of managing blood pressure in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Lean: BMI \< 25 kg/m
- • Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood)
- • Middle-aged: 18-79 years
- • Blood pressure: \< 140 (systolic) and \< 90 mmHg (diastolic
- • Weight stable (+/- 5 lbs) for the previous 3 months
- • Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
- • Able and willing to provide written informed consent
- Exclusion Criteria:
- • Diabetes mellitus Type I or Type II: fasting glucose \< 126 mg/dL and/or HbA1c \< 6.5%
- • Current smoker or History of smoking in the past 3 months.
- • Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
- • Hypertension: \>130/80 mmHg
- • History of heart disease (e.g., myocardial infarction, stent, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
- • History of vascular disease (e.g., bypass, stroke)
About University Of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, KUMC leverages its extensive expertise in diverse medical fields to conduct rigorous clinical research aimed at improving patient outcomes and developing new treatment modalities. With a commitment to ethical standards and patient safety, KUMC collaborates with multidisciplinary teams to facilitate groundbreaking studies that address significant health challenges, ultimately contributing to the advancement of medical knowledge and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Trial Officials
Seth W. W Holwerda, PhD
Principal Investigator
University of Kansas Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials